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Abstract
In man, infection with South American Andes virus (ANDV) causes hantavirus cardiopulmonary syndrome (HCPS). HCPS due
to ANDV is endemic in Southern Chile and much of Argentina and increasing numbers of cases are reported all over South
America. A case-fatality rate of about 36% together with the absence of successful antiviral therapies urge the development
of a vaccine. Although T-cell responses were shown to be critically involved in immunity to hantaviruses in mouse models,
no data are available on the magnitude, specificity and longevity of ANDV-specific memory T-cell responses in patients.
Using sets of overlapping peptides in IFN-c ELISPOT assays, we herein show in 78 Chilean convalescent patients that Gn-
derived epitopes were immunodominant as compared to those from the N- and Gc-proteins. Furthermore, while the relative
contribution of the N-specific response significantly declined over time, Gn-specific responses remained readily detectable
ex vivo up to 13 years after the acute infection. Tetramer analysis further showed that up to 16.8% of all circulating
CD3
+CD8
+ T cells were specific for the single HLA-B*3501-restricted epitope Gn465–473 years after the acute infection.
Remarkably, Gn465–473–specific cells readily secreted IFN-c, granzyme B and TNF-a but not IL-2 upon stimulation and
showed a ‘revertant’ CD45RA
+CD27
2CD28
2CCR7
2CD127
2 effector memory phenotype, thereby resembling a phenotype
seen in other latent virus infections. Most intriguingly, titers of neutralizing antibodies increased over time in 10/17
individuals months to years after the acute infection and independently of whether they were residents of endemic areas or
not. Thus, our data suggest intrinsic, latent antigenic stimulation of Gn-specific T-cells. However, it remains a major task for
future studies to proof this hypothesis by determination of viral antigen in convalescent patients. Furthermore, it remains to
be seen whether Gn-specific T cells are critical for viral control and protective immunity. If so, Gn-derived immunodominant
epitopes could be of high value for future ANDV vaccines.
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Introduction
The family Bunyaviridae is comprised of five genera of tri-
segmented negative-stranded RNA viruses, which are responsible
for a considerable burden of zoonotic disease in man. While most
are tick- or mosquito-borne, members of the genus Hantavirus are
transmitted from chronically- and asymptomatically-infected
rodents to humans via aerosols, which may derive from urine,
feces or saliva. Globally hantaviruses may cause as many as
200,000 cases of human disease per year. In man, two clinical
conditions may arise: hemorrhagic fever with renal syndrome,
caused by the Asian and European strains (e.g. Hantaan, HTNV
and Puumala, PUUV) or hantavirus cardiopulmonary syndrome
(HCPS), which is caused by Sin Nombre virus (SNV) and Andes
virus (ANDV), among others in the Americas. HCPS is an
emerging infectious disease in North- and South America [1-5]
and, currently, Chile represents among the most endemic regions
for HCPS with more than 580 cases since 1995 [6].
As for ANDV, transmission to man is followed by infection of
lung endothelial cells and, after an incubation period of 7 to 39
days [7], the development of a vascular leakage syndrome,
eventually leading to massive pulmonary edema, shock and, in
many cases, death. The high case-fatality ratio (mean 36%), the
absence of a proven antiviral treatment or a vaccine, their mode of
transmission and their potential use as weapons for bioterrorism,
have rendered HCPS-causing hantaviruses Category A pathogens
within NIAID’s biodefense program [8]. Importantly, ANDV is
the only hantavirus for which person-to-person transmission has
been repeatedly documented [9–11].
The hantavirus virion contains a lipid-bilayer envelope into
which both constituents, the Gn and Gc antigens of the heteromeric
glycoprotein, are inserted via transmembrane domains. In the viral
core, there are three nucleocapids each consisting of the RNA-
binding N or nucleocapsid protein in complex with one of the
genomic RNAs. These mRNAs encode the RNA-dependent RNA
polymerase or L protein on the large or L segment (2153aa), the Gn
PLoS Pathogens | www.plospathogens.org 1 February 2010 | Volume 6 | Issue 2 | e1000779(650aa) and Gc (490aa) glycoproteins on the middle or M segment,
and the N protein (430aa) on the S segment [12].
Currently, there is a big discrepancy regarding the role of T cells
in either pathogenesis or immunity of hantavirus infections. On
one hand some studies in SNV-infected patients describe a
correlation between the severity of HCPS and either the frequency
of SNV-specific CD8
+ T-cells [13] or the HLA-B35 haplotype
[14], suggesting a T-cell driven pathogenesis of HCPS. On the
other hand, several early reports highlight the importance of
lymphocytes for immunity of mice towards hantaviruses, such as
HTNV [15–17]. Likewise, clearance of HTNV in newborn mice
was dependent on TNF-a production and cytotoxic activity of
specific CD8
+ T cells [18]. In addition, (HTNV-) N-protein-
specific memory T-cells conferred partial protection and cross-
protection towards N-expressing vaccinia virus [19] or hantavi-
ruses [20] in mice and Syrian hamster [21,22], respectively. In line
with these findings we have recently reported that clearance of
ANDV-RNA from peripheral blood cells of a patient was closely
related to the appearance of cytotoxic CD8
+ T cells about two
months after the acute infection [23]. This observation together
with the finding that we were unable to detect memory T-cells in
many of the survivors of ANDV-induced HCPS (see below) led us
to the hypothesis that T-cells may be crucial for protection and
immunity towards ANDV rather than the pathogenesis in ANDV-
infected patients. Concisely, knowledge of targeted epitopes and
functional properties of ANDV-specific T-cells in ANDV-survivors
may be important for both future studies in acutely ill patients and
possibly for vaccine development.
Despite its importance, the knowledge of the human cellular
immune response to hantaviruses is limited. To date, only few
studies have assessed SNV-, HTNV- or PUUV- specific T cells
[13,24–28] in rather small patient cohorts and based on individual
in-silico-predicted peptides and/or T-cell lines that had been
expanded in vitro. Thus, the overall magnitude of human T-cell
responses in vivo and the epitope-hierarchy within the memory
T-cell pool in convalescent patients remains uncertain. Also,
phenotype, effector functions and longevity of specific memory T-
cells in humans remain to be elucidated. Greater knowledge of
these matters would likely to be of high value to potential vaccine
developers.
In an effort to gain insight into human cellular immunity to
ANDV and to establish an immuno-hierarchy among ANDV-
antigens, we carried out a study of the viral protein-specific T cell
responses in 78 Chilean patients with past ANDV-infection. Our
findings on the immuno-hierarchy among major structural
hantavirus proteins and the frequencies as well as the functional
features of CD8
+ memory T cells may be of special interest for
vaccine development since all attempts to induce long-lasting
neutralizing humoral immunity have been unsuccessful so far [29].
Results
Gn of ANDV is highly immunogenic
In order to quantify circulating ANDV-specific T-cells ex vivo
and to determine the immunodominant epitopes of ANDV, we
first challenged PBMC of 78 Chilean convalescent patients
(between 4 months and 13.2 years after hospitalization due to
infection) with 310 overlapping peptides (distributed in 13 pools)
spanning the entire N- and Gn/Gc precursor proteins [30] in IFN-
c ELISPOT assays.
Based on the criteria we used to score a sample as ‘‘positive’’ (see
Material and Methods), 51 (66%) of the 78 patients showed
significant responses against epitopes of at least one of the three
viral antigens (Fig. 1A). Among these patients, 33/51 (65%)
showed significant responses against epitopes of the N-protein,
while 13/51 (25%) showed Gc-specific T-cells (Fig. 1B). However,
80% (41/51) of the positive patients launched significant responses
towards Gn-derived epitopes. Moreover, while mean responses
among the 51 individuals reached the sum of 1809 Spot Forming
Units (SFU)/10
6PBMC when considering all viral antigens, Gn-
specific responses accounted for more than half of the total
response, at 973 SFU/10
6PBMC (Fig. 1C) as compared to 697
and 139 SFU/10
6 PBMC for N- and Gc-epitopes, respectively.
Since all patients were BCG-vaccinated twice during childhood,
we determined BCG-specific T cells (n=10), resulting in a mean
of 162 SFU/10
6 PBMC. Thus, Gn is the immunodominant
antigen in ANDV-convalescent individuals.
Relative stability of the Gn- and Gc-specific memory
T-cell pool
We next asked whether differences in the longevity of each of the
specific T-cell categories could account for the relative immunodo-
minance of Gn among ANDV antigens, e.g., whether Gn-specific
cells might persist longer than did cells responsive to the other
antigens. We therefore considered the numbers of circulating N-,
Gn- and Gc-specific T cells of each patient in relation to the time
between the patient’s hospital admission due to HCPS and the
timepoint at which T cells were applied to ELISPOT assays
(Fig. 2A–C). Although this approach does not allow to draw
conclusionsonthe slopeofantigen-specificresponsesatthelevelofa
given individual, it is possible to directly compare the different
antigen-specific responses within the overall cohort over time.
Similar approaches have been previously performed on a cohort of
smallpox vaccinees in order to estimate longevity and half-life of
cellular and humoral memory responses [31].
Interestingly, only the N-specific response (Fig. 2A) exhibited a
negative and significantly descending linear regression slope over
Author Summary
In man, hantavirus cardiopulmonary syndrome (HCPS)
caused by Andes Virus (ANDV) is endemic in the Southern
cone of Chile and Argentina but cases of HCPS are being
increasingly reported all over South America since 1995.
HCPS is characterized by fulminant pulmonary edema
which progresses to shock and death in about 36% of
patients with HCPS. Nevertheless, to date, neither antiviral
treatments nor vaccines inducing neutralizing antibodies
(NAb) have proven effective against HCPS-causing hanta-
viruses. We set out for the first study on human cellular
immunity towards ANDV in 78 convalescent survivors of
ANDV infection. We found that Gn-specific responses were
predominant as compared to N- and Gc-specific responses,
even up to 13 years after the infection. Surprisingly, most
of the Gn-specific responses were restricted to two
neighboring epitopes within the Gn carboxyterminus.
Interestingly, among HLA-B*3501
+ patients, Gn4652473-
specific CD8
+ T-cells showed highly differentiated but
resting phenotype and functions. It remains to be seen in
future studies whether the immunodominace of Gn-
specific T-cells is crucial for protective immunity. Most
intriguingly, titers of neutralizing antibodies increased in
10/17 individuals months to years after the acute infection
and independently of whether they were residents of
endemic areas or not. Thus, our data suggest viral per-
sistence or latency in part of ANDV-convalescent patients.
However, it remains a major task for future studies to proof
the concept of latent/persistent human ANDV infection by
the determination of viral antigen in convalescent patients.
Memory T-Cell Response in ANDV-Infected Patients
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specific responses (Fig. 2B, C) (r=0.07 and r=0.02, respectively).
We next segregated the 51 patients with positive T-cell responses
into six groups according to the time past since hospitalization
due to ANDV-infection (,1, 1–2, 2–4, 4–6, 6–9 and .13 years,
respectively). As can be seen in Figure 2D, up to four years after
infection N-specific responses were predominant, whereas after-
wards Gn-specific relative contributions to the overall T-cell
response increased from approximately 40% to more than 80%
(Fig. 2D). Taken together, these data suggest that Gn- and Gc-
specific T-cell responses are more stably maintained as compared
to N-specific responses. However, in light of the limited value of
the cross-sectional data available to us, future prospective studies
assessing individual T-cell responses from the acute to the
convalescent phase in individual patients would be needed to
determine the absolute half-life of the N-, Gn- and Gc-specific
T-cell responses.
Immunodominance of Gn461–475 within the Gn
carboxyl-terminus
Subsequently, results from IFN-c ELISPOT assays revealed
that regions Gn1-230 and Gn221–450 elicited a mean of 102 and 209
SFU/10
6 PBMC in 34% and 38% of all responsive patients,
respectively (Fig. 3A). However, Gn441–650 elicited a mean
response of 623 SFU/10
6PBMC (range 0–5506 SFU/10
6PBMC)
in 24/51 (46%) patients. These data clearly indicate that epitopes
within the carboxyl-terminus of Gn of ANDV are responsible for
the immunodominance of Gn among ANDV-convalescent indi-
viduals. In contrast to the strong Gn-specific responses, Gc641–815
and Gc806–980 elicited a response in 24% (77 SFU/10
6PBMC) and
11% (25 SFU/10
6PBMC) of all patients, whereas Gc971–1140 was
targeted by only 4% (30 SFU/10
6PBMC) of patients (data not
shown).
We next stimulated cryopreserved PBMC from patients with
Gn441–650-specific response using peptide pools representing
Gn441–505,G n 496–560,G n 551–615 and Gn606–650, respectively. This
approach revealed that region Gn441–505 comprised the major
epitopes of Gn441–650 (data not shown). We then challenged
cryopreserved PBMC of 11 patients with individual peptides
spanning region Gn441–505. As shown in Figure 3B, only three
patients (p30, p40, p59) exclusively recognized peptides Gn451–465
and Gn456–470, whereas p17 and p57 additionally recognized
Gn461–475 and Gn466–480. By contrast, six patients (p6, p10, p15,
p28, p32, p53) showed exclusive recognition of Gn461–475 and
Gn466–480. Thus, a total of five patients recognized Gn451–465/
Gn456–470, whereas eight patients recognized Gn461–475/Gn466–480.
Subsequently, four additional individuals with exclusive and
significant responses towards Gn461–475/Gn466–480 were identified
(data not shown).
Together with a previous report from our lab [23], these epitopes
are the first described within the Gn-region of hantaviruses. In
addition, we determined immunodominant regions of ANDV
N-protein, which included N1–70 (24.3% of responsive patients
elicited a significant response) and N121–190 and N181–250 (21.2%
and 19.5%, respectively) eliciting mean responses of 113–147
Figure 1. Distribution of ANDV-specific memory T-cell responses. (A) Summary of the determination of ANDV-specific T cells ex vivo IFN-c
ELISPOT assay in a total of 78 ANDV-convalescent patients. According to the criteria for positivity (see material and methods) only 51/78 (65%)
displayed a positive response. Alternating black and white bar graphs (one bar represents one individual) are used for better visibility. (B) Differential
recognition of ANDV antigens among the 51 responsive patients, indicating the relative immunodominance of Gn- as compared to N- and Gc-
protein. (C) Individual T-cell responses to the different ANDV-antigens and BCG. Triplicates of PBMC of each patient were challenged in a 38-hour IFN-
c ELISPOT by a total of 13 pools of overlapping peptides, spanning the entire N- (aa 1–430), Gn- (aa 1–650) and Gc- (aa 641–1140) protein of Chilean
ANDV. Most patients showed significant responses towards the Gn-antigen (aa 1–650). Each bar represents the sum of mean triplicate responses
towards the peptides representing a given antigen. Depiction of standard-deviations was avoided to facilitate the visibility of results. The overall
mean response to ANDV was 1805 SFU/10
6 PBMC.
doi:10.1371/journal.ppat.1000779.g001
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6PBMC (data not shown). Downmapped individual
epitopes within the N-protein are summarized in Table 1.
We next wondered, which state of differentiation was expressed
by the IFN-c producing memory CD8
+ T cells. Intracellular
cytokine staining showed that IFN-c
+CD8
+CD45RO
+ T-cells
expressed varying levels of CD45RA but consistently expressed a
CCR7
2CD28
2CD27
2 effector memory phenotype (Fig. 3C). In
line with this terminally differentiated phenotype, 25% of all
IFN-c
+ T cells secreted granzyme B upon stimulation with their
cognate peptide (Fig. 3D) whereas no IL-2 could be detected (data
not shown). In addition, up to 45% of these IFN-c
+CD8
+ memory
T cells co-expressed TNF-a as determined by ICS (data not
shown). These findings suggest that even years after acute ANDV
infection (e.g. p32 and p40 were investigated 5.4 and 13.2 years
after hospitalization, respectively), high frequencies of cytolytic
memory CD8
+ T-cells are maintained in the periphery.
Impact of HLA-B*35- restricted responses on clinical
outcome
As both the Gn451–465/Gn456–470 and Gn461–475/Gn466–480
epitopes share 10 amino acids in sequence within the pairs, we
reasoned that one CD8
+ T-cell epitope may be located within each
overlapping sequence, respectively (e.g. Gn456–465 and Gn466–475).
In support of this hypothesis, the analysis of HLA-A, -B, -DR and
-DQ alleles revealed that 5/5 patients with response towards
Gn451–465/Gn456–470 exclusively shared the HLA-A*24 allele (data
not shown), whereas the HLA-B*35 allele was the only allele
shared by all 12 patients recognizing Gn461–475/Gn466–480
(Fig. 4A). These data suggest the existence of two separate but
neighboring CD8 T-cell epitopes in the carboxyterminal region of
Gn that are restricted by HLA-A*24 and HLA-B*35, respectively.
Indeed, as shown in Figure 4B, a significant response in a Gn461–475
–specific T-cell line could only be detected when the HLA-B*35
allele was present on heterologous APCs (B-LCL).
It was previously suggested that severe HCPS due to SNV is
associated with the HLA-B*35 allele [14] and with CD8 T-cell
responses restricted to it [13]. We therefore were interested in the
relation of memory T-cell responses and outcome of their ANDV
infection in HLA-B*35-positive and negative patients (Fig. S1).
Among all 78 patients, that is patients with (n=51) and without
(n=27) significant memory T-cell responses, no differences in
overall T-cell responses could be observed when comparing HLA-
B*35-negative patients with mild or severe HCPS (Fig. S1A). By
contrast, we found an about 3-fold higher overall T-cell response
in HLA-B*35-positive patients with mild HCPS as compared to
both HLA-B*35-positive patients with a history of severe disease
and either group of HLA-B*35-negative patients (Fig. S1B).
Likewise, 10/12 (83%) HLA-B*35-positive patients with signifi-
cant responses to Gn461-475 had a history of mild HCPS (Fig.
S1C). Thus, these data suggest that HLA-B*35-restricted memory
T-cell responses are related to mild rather than to severe disease
outcome.
We next sought to determine the optimal epitope of Gn461–475/
Gn466–480 (Fig. 4C). Because we consistently observed stronger
immune responses towards Gn461–475 (SLFSLMPDVAHSLAV)
than towards Gn466–480 (MPDVAHSLAVELCVP), we reasoned
that Leucine at position 465 may increase either the binding
affinity or the TCR-recognition of the overlapping sequence
Gn466–475 (MPDVAHSLAV). We therefore decided to generate
Gn461–475–specific T-cell lines from HLA-B*3501 individuals and
then challenged these cells with cleaved peptides of Gn465–475
Figure 2. Relative contributions of antigen-specific memory T-cell responses over time. Association between N- (A), Gn- (B) and Gc-
specific (C) memory T-cell responses and the time past between hospitalization and enrollment of a given patient. (D) Mean of antigen-specific
contributions to absolute overall T-cell responses (defined as 100%, respectively) among 51 patients with positive T-cell responses and segregated
into six groups according to the time past since hospitalization due to ANDV-infection. The numbers within the bar graphs indicate the relative
percentages of N-, Gn- and Gc-specific responses, respectively.
doi:10.1371/journal.ppat.1000779.g002
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PLoS Pathogens | www.plospathogens.org 4 February 2010 | Volume 6 | Issue 2 | e1000779Figure 3. Downmapping of Gn-derived epitopes and characterization of specific T cells. (A) Gn-specific T-cell responses among the 51
positive patients, according to amino-terminal (aa 1–230), central (aa 221–450) and carboxy-terminal (aa 441–650) region. Each bar represents the
sum of mean triplicate responses towards the peptides representing a given region. (B) aa 451–480 of Gn comprises of highly immunogenic epitopes
and is recognized by 8/11 patients with strong responses towards the carboxyterminus of Gn. (C) Surface marker staining of PBMC of specific, IFN-c
secreting CD8
+CD45
+ after stimulation with 10 mg/ml of Gn- and N-derived 15mer peptides, indicating a predominantly end-differentiated
phenotype of specific CD8 memory T-cells. DMSO and PMA/Ionomycin were used as control stimuli. (D) A high percentage of IFN-c secreting Gn-
specific CD8 memory T-cells readily secretes granzyme B upon ex-vivo stimulation with their cognate peptide years after acute ANDV-infection (e.g.
p32: 13.2 yrs, p40: 5.4 yrs post hospitalization, respectively).
doi:10.1371/journal.ppat.1000779.g003
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carboxyterminal Leucine at position 473 led to a complete loss of
epitope recognition. Similarly, elimination of the aminoterminal
Methionine at position 466 was critical for epitope recognition.
Most interestingly, virtually identical results were obtained when
cells from HLA*B3501, HLA-B*3502 and HLA-B*3505 individ-
uals were challenged with cleaved peptides, indicating that the
Gn466–473 epitope is equally immunogenic among different HLA-
B*35 subtypes.
High frequencies of memory CD8
+ T cells that have the
potential to exert cytotoxic function are maintained in
the periphery
We next were interested in comparing the phenotype of Gn465–
473 restricted T cells and with other HLA-B*3501-restricted virus-
specific T cells in seven HLA-B*3501 positive ANDV-convales-
cent patients (Fig. 5A, B). The mean abundance of Gn465–473
specific T-cells was higher than those specific for N131–139 and
Gc664–673 –epitopes, described by Kilpatrick et al. [13], the latent
EBV-epitope EBNA3A458–466 [32], the Influenza A NP418–426
epitope [33], or the Rv2903c201–209 epitope of Mycobacterium
tuberculosis, known to be recognized by BCG-vaccinated individuals
[34].
In the seven HLA-B*3501-positive individuals we had detected
between 0 and 4394 SFU/10
6 PBMC (0%–0.0044%) following
stimulation with peptide Gn461–475 in IFN-c ELISPOT assays.
When normalizing the results by the percentages of CD3
+CD8
+
cells in these individuals (range 9.9–33.9% of PBMC, mean
19.7%), one would have expected between 0% (p45) and 0.036%
(p17) of CD3
+CD8
+ cells being tetramer positive. However, we
found 0.3% and 5.9% of all CD3
+CD8
+ T cells being positive for
Gn465–473:HLA-B*3501 tetramer complexes, respectively. In
addition, the highest frequencies for tetramer-positive cells were
found in patient 10 (16.8% of CD3
+CD8
+ cells), whereas only
0.0111% of his CD3
+CD8
+ cells produced IFN-c in ELISPOT
assays. This discrepancy between both detection methods is in line
with previous reports [35].
We next determined the state of differentiation of Gn465–473-
specific T-cells, where a clear dichotomy was observed (Fig. 6A,
B). In patients with positive responses towards Gn461–475 in IFN-c
ELISPOT assays (IFN-c
++), Gn465–473 specific T cells were mostly
CD45RA
+CCR7
2 and significantly more of a differentiated
CD28
2CD27
2 phenotype as compared to IFN-c
2 samples. In
addition, we found significant differences with regard to the
IL-7Ra (CD127), which is crucially involved in maintenance of
memory T-cells in the periphery in the absence of cognate antigen
[36]. Patients with IFN-c
+ ELISPOT results showed mainly
CD127
2 Gn4652473 T cells, whereas T cells of IFN-c
2 patients
were mostly CD127
+ (Fig. 6A, C). Thus, Gn4652473-specific
CD8
+ T cells showed a phenotype that is clearly distinct relative to
that described for other self-limited diseases such as those caused
by influenza A and respiratory syncytial virus but more resembled
the pattern associated with latent infections, such as past exposure
to CMV [37]. Because a CD28
2CD27
2CD127
2 phenotype was
previously described to be a result of ongoing antigen-stimulation,
as found in latent CMV infection, we next determined the
expression of activation markers, such as of KLRG-1, CD69,
CD38 and CD25 on Gn465–473 and Influenza A-specific T cells
within the seven HLA-B*3501
+ ANDV-convalescent (Fig. 6D).
No significant differences could be observed between IFN-c
+ and
IFN-c
2 Gn465–473-specific populations or between Gn465–473- and
Influenza A NP418–426-specific T-cells.
Prospectively high frequencies of Gn-specific memory
T cells, anti-N antibodies and neutralizing antibodies
In a next step we assessed whether re-exposure to viral antigens
could have led to a boost in the donor’s immune response. We
therefore compared memory T-cell responses in patients who got
infected during recreation (R-patients) with those of residents in
endemic areas (E-patients) (Fig. 7A). No significant differences
were observed between the two groups in those responses,
although endemic patients revealed about double as many Gn-
specific memory T-cells than recreational patients (mean 765 vs
361 SFU/10
6 PBMC) for unclear reasons. However, these results
are not in line with the hypothesis of repeated viral exposure in
patients who reside in endemic areas, since N- and Gc-specific
responses were virtually identical in both groups.
In addition, we identified seven individuals, which had been
infected during recreation (R-patients, Fig. 7B, C) and ten
individuals residing in endemic areas (E-patients, Fig. 7D, E), for
all of which two prospective serum samples were available. The
time period between sample 1 and sample 2 was 0.3–6.9 years and
1.2–4.1 years in R- and E-patients, respectively. Surprisingly, in
R- and E-patients anti-N titers raised four- to 64-fold between
samples 1 and 2 in 4/7 and 5/10 patients, respectively. Most
intriguingly, however, also neutralizing antibody (NAb) titers rose
two- to eight-fold in 4/7 and 6/10 of R- and E-patients,
respectively. Importantly, NAb titers, measured by a blinded
worker, increased two- to four-fold in patients R1, R3, R5, E1 and
E4 between sample timepoint 1 and 2, although in all cases sample
1 was taken months to years after the acute phase. Taken together,
these results suggest that re-exposure to extrinsic, environmental
virus is not responsible for the observed rise in NAb titers or high
frequencies of memory T cells.
Finally, we sought to prospectively study Gn-specific T-cells in
three patients. When Gn465–473-specific T cells were phenotyped
over a time period of two years (Fig. 8A–C), no dynamic changes
of the CD27
2 population could be observed, indicating that
differentiated Gn465–473-specific T cells are able to stably persist at
Table 1. Determined T-cell epitopes within the ANDV N-
protein and observed range(s) of response(s).
Epitope,
aa region Peptide sequence
(Range of) response(s)
(SFU/106 PBMC)
N41–55 KSTLQSRRAAVSTLE 183
N46–60 SRRAAVSTLETKLGE 1760
N61–75 LKRQLADLVAAQKLA 120–143
N106–120 SIDLEEPSGQTADWK 490–807
N126–140 ILGFAIPIILKALYM 116–645
N131–145 IPIILKALYMLSTRG 143–464
N141–155 LSTRGRQTVKDNKGT 232
N146–160 RQTVKDNKGTRIRFK 37–277
N186–200 STMKAEEITPGRFRT 83
N191–205 EEITPGRFRTIACGL 180–743
N221–235 GVIGFGFFVKDWMDR 313
N226–240 GFFVKDWMDRIEEFL 1700
N231–245 DWMDRIEEFLAAECP 270–360
N236–250 IEEFLAAECPFLPKP 150–426
N241–255 AAECPFLPKPKVASE 117
N251–265 KVASEAFMSTNKMYF 210
doi:10.1371/journal.ppat.1000779.t001
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mediated survival signals. However, in patients E9 and E2
(Fig. 8A, C, respectively), Gn465–473-specific T cells actually
increased over time, paralleling the two- to eight-fold increase in
NAb titers observed in these two individuals (Fig. 7E).
Discussion
Infection with ANDV is the predominant cause for HCPS in
South America. Case-fatality rates of currently 36%, person-to-
person transmission and the absence of a proven effective antiviral
treatment urge the development of a vaccine. Although the
protective potential of neutralizing antibodies against the hanta-
virus surface glycoproteins Gn and Gc, but not the N-protein, was
established in vitro [38–40] and in animal models [41–43], efforts to
induce long-lasting neutralizing antibodies in human volunteers
have been unsuccessful so far [29,44] or remain to be proven
effective and long lasting [45].
On the other hand, several early reports highlight the
importance of lymphocytes for immunity of mice towards
hantaviruses, such as HTNV [15–17]. Likewise, appearance of
virus-specific CD8
+ T cells with cytotoxic activity and the ability to
produce IFN-c and TNF-a was associated with clearance of
HTNV in newborn mice. In contrast, HTNV infection was not
cleared when TNF-a production and cytotoxic activity of specific
CD8
+ T cells were impaired [18]. In another report, (HTNV-)
N-protein-specific CD8
+ memory T-cells, induced by a DNA
vaccine, conferred partial protection against re-challenge with a
Figure 4. HLA-restriction and minimal optimal epitope of Gn461–475. (A) Frequency of HLA-A- and B-alleles among individuals with positive
response towards Gn461–475, indicating that HLA-B*35 is the only allele in common. (B) HLA-B*35-restriction of Gn461–475. Two Gn461–475–specific T-cell
lines were generated over 21 days and then stimulated by Gn461–475 in the presence of autologous or heterologous APCs (B-LCL). * indicates
significant responses (p,0.05). (C) downmapping of the minimal epitope of Gn461–475 Gn. Truncated versions of Gn461–475 were used to stimulate a
21-day Gn461–475–specific T-cell line (left panel) derived from a HLA-B*3502-positive donor in an 24 hour IFN-c ELISPOT assay. Identical results were
obtained with cell lines from two HLA-B*3501-positive individuals (data not shown) and in an ex vivo ELISPOT assay using PBMC from a HLA-B*3505-
positive individual (right panel).
doi:10.1371/journal.ppat.1000779.g004
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showed that N-protein specific T cells rather than antibodies
mediated protection and cross-protection upon re-challenge with
homologous and heterologous hantaviruses [20]. Finally, ANDV
infection of Syrian hamsters - the sole animal model for human
HCPS–could be prevented for at least 10 months by previous
vaccination with ANDV N-protein [21], again indicating that
protection can be achieved independently of neutralizing, Gn/Gc-
specific antibodies. Most recently Safronetz et al. confirmed these
findings in Syrian hamsters vaccinated with Gn-protein expressing
Adenovirus vectors. Interestingly, these animals were protected
from lethal ANDV infection independently of neutralizing
antibodies and showed no or very low levels of ANDV-RNA up
to 9 days after ANDV infection [22]. As for ANDV-infection in
man, we recently showed that clearance of ANDV-RNA from
peripheral blood cells was closely related to the appearance of
cytotoxic CD8
+ T cells, but not NAb, in a patient about two
months after the acute infection [23].
Taken together, these reports suggest that cytotoxic T cells are
crucially involved in clearance and protection from hantaviruses.
Conversely, establishment of hantavirus-specific cytotoxic memory
CD8
+ T cells prior to infection, e.g. by a vaccine, may provide
protective, albeit not sterilizing, immunity to the host. However,
limited information on human cellular immunity to hantaviruses
is available and, to date, only one study addresses ANDV-specific
T-cell responses [23].
Using a panel of 310 overlapping peptides spanning the entire
N-, Gn- and Gc-protein of ANDV allowed us to study most,
existing T-cell epitopes in 78 convalescent survivors of ANDV
infection in a non-HLA-restricted manner. In contrast to other
reports with a similar approach, the majority of responses were
specific for Gn- but not N-protein-derived epitopes. Thus, our
Figure 5. Tetramer analysis of pathogen specific CD8+ memory T cells in seven HLA-B*3501
+ individuals. (A) staining of CD3
+ cells
using HLA-B*3501:tetramer complexes (see table 2). (B) Frequencies of tetramer
+CD3
+CD8
+ cells found in seven HLA-B*3501-positive ANDV-
convalescent individuals.
doi:10.1371/journal.ppat.1000779.g005
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dogma of N-protein being the principal T-cell immunogenic
hantavirus antigen [19,20,22,24,25,27,46-48]. However, in previ-
ous studies, epitope-specific T cells were detected either by in vitro
expansion prior to testing or using individual peptides or tetramer
complexes for ex vivo detection in a small and HLA-selected patient
populations [13,24–28]. Thus, differences in the experimental
design, rather than its elevated immunogenicity, may explain, why
we found Gn being the immunodominant antigen of ANDV,
whereas no single Gn-epitope had been described for other
hantaviruses. In fact, 92–96% of the amnio acid sequence of the
two Gn-epitopes described herein, are conserved within the
PUUV and SNV sequence, respectively. An alternative explana-
tion may derive from the differences between our study and other
studies in the timing of T-cell testing after the acute phase or
differences in infection kinetics between the different hantaviruses.
Specifically, as can be seen in Figure 2D, N-derived epitopes
seemed to be relatively predominant up to four years after the
acute infection, whereas Gn-derived epitopes were predominant in
patients with a longer convalescence phase. In addition, the
kinetics of NAb titers in our patients suggest that viral antigen
may be present for months or years after the acute infection, a
Figure 6. Phenotypic analysis of Gn465–473-specific subsets and comparison with (Influenza) NP418–426-specific CD8
+ T cells. (A)
Gn465–473:tetramer
+CD3
+CD8
+ cells predominately express a a CD28
2CD27
2CD127
2 phenotype. (B) Patients with Gn461–475-specific responses in
IFN-c ELISPOT (n=4) assays show significantly more (p,0.01) highly differentiated CD28
2CD27
2 Gn465–473:tetramer
+CD3
+CD8
+ cells than those
individuals without IFN-c responses (n=3). No significant differences were observed as regards to expression of CD45RA and CCR7. (C) Patients with
Gn461–475-specific responses in IFN-c ELISPOT (n=4) assays show significantly less (p,0.001) CD127
+ Gn465–473:tetramer
+CD3
+CD8
+ cells than those
individuals without IFN-c responses (n=3). By contrast, no clear differences were observed as regards to Influenza-specific T-cells of the same
individuals. (D) No signs of significant activation could be observed in Gn465–473:tetramer
+CD3
+CD8
+-specific cells as when compared to Influenza A
NP418–426:tetramer
+CD3
+CD8
+-specific cells.
doi:10.1371/journal.ppat.1000779.g006
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Thus, differences in epitope avidity and/or precursor expansion
over time may have contributed to the relative predominance of
Gn-specific T-cells in our study.
Of note, 80% of all patients with detectable T-cell responses
recognized Gn-derived epitopes (Fig. 1B). To our surprise, however,
responses against Gn were not broad but rather focused to the
carboxyterminus of Gn, namely the region of aa 451–480.
Interestingly, the cytoplasmic tail of Gn has been shown to contain
important virulence factors as it suppresses type 1-interferon res-
ponses in infected cells [49,50]. On the other hand, the carboxy-
terminal 142 residues of pathogenic (namely of ANDV and HTNV),
but not non-pathogenic hantaviruses, prone the C-terminal tail of
Gn towards degradation by the proteasome, which then leads to the
presentation of epitopes by MHC I molecules to CD8
+ T-cells [51].
This mechanism could explain the relative immunodominance of
Gn-derived epitopes seen in our study and also may represent a
virulence factor of ANDV suggesting that T cells are causative for
HCPS. Nonetheless, an early and vigorous cytotoxic T-cell response
towards epitopes of the C-terminal Gn may also be able to
restrict the virulence of ANDV infection. Indeed, among HLA-
B*35-positive patients mild disease outcome seemed to be associated
with stronger responses towards the Gn-carboxyterminus than in
patients with severe HCPS (Fig. S1B, C). In line with this finding, a
recent study in 87 Chilean ANDV-infected patients found that the
HLA-B*35 allele was the most frequent allele among patients with
Figure 7. Comparison of immune responses between patients residing in endemic areas (E-patients) and those who got infected
during recreation (R-patients). (A) no significant differences in memory T-cell responses between E- and R-patients. (B-E) prospective anti-N
(determined by indirect ELISA) and NAb titers (determined by FRNT) in R-patients (B, C) and E-patients (D, E), respectively. Symbols filled in grey
indicate patients in who sample 1 was taken months or years after the acute infection; the time difference between the acute phase and the
timepoint of sample 1 is indicated as negative number in parenthesis (legend on the right). The second number indicates the time period between
sample 1 and sample 2, respectively.
doi:10.1371/journal.ppat.1000779.g007
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disease[52]. Althoughthese data seemtocontradictpreviousreports
describing both the expression of the HLA-B*35-allele [14] as wellas
HLA-B*35-restricted T-cell responses [13] as risk factors for severe
HCPS by SNV, it remains speculative whether our results indicate
anpivotalroleforTcellsindiseaseoutcome.Thesizeofthememory
T-cell pool is only indirectly linked to the effector T-cell response by
the original burst size [53] and therefore may not reflect the size and
composition of the effector T-cell pool during the acute phase.
Moreover, 33% of HLA-B*35-negative patients and 48% of patients
without any detectable memory T-cell responses had a history of
mild HCPS (data not shown). Likewise, 52% of patients with severe
HCPSdid notshowmemoryT-cellresponses(datanot shown).Both
seemtoargueagainstanexclusiveroleofTcellsfordiseaseoutcome.
In addition, other hand, we also showed a discrepancy between
ELISPOT and tetramer-derived T-cell frequencies (see above),
which indicates the existence of IFN-c-negative ANDV-specific
T-cells. In fact, three of the seven studied HLA-B*3501 positive
donors did not show significant responses in initial IFN-c ELISPOT
assays (Fig. 1) but showed substantial numbers of tetramer-positive
CD3
+CD8
+ T cells. This is in line with previous reports comparing
determination of T-cell frequencies by ELISPOT and tetramer
analysis [35]. In this report tetramer analysis revealed on average
ten-fold higher frequencies than IFN-c ELISPOT assays of T cells
specific for a HLA-A2-restricted HIV Gag-derived peptide. This
report as well as our data suggests that the vast majority of
Figure 8. Prospective analysis of Gn465–473–specific T cells in three HLA-B*3501
+ individuals. Cryopreserved PBMC samples of each donor
(A–C) and year were thawed and processed in parallel and assayed together in order to guarantee optimal comparability of the samples. Upper
panels of each patient are gated on PI
2CD3+ T-cells, lower panels show CD27 expression gated on tetramer
+CD3
+CD8
+ cells, respectively. Note that
(A) is showing frequencies of patient E9 and (C) of patient E2 (compare with Figure 7E).
doi:10.1371/journal.ppat.1000779.g008
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by peptides in ELISPOT assays. It is also possible that these T cells
were functional during the acute phase but not during convales-
cence. Alternatively, differences inthe infectious dose(e.g. low versus
high infectious dose) or the kinetics and doses of the evolving
neutralizing antibodies may interfere with the functional quality of
the memory T-cell pool. Taken together, additional studies with
HLA-tetramers in acutely ANDV-infected patients will be necessary
to better understand the role of HLA-B*35 and T-cell kinetics for
ANDV disease outcome.
Another interesting aspect of our study concerns the longevity of
the memory T cells in association with their highly differentiated
phenotype. After more than 13 years after infection we still
detected 564–2152 SFU/10
6 PBMC by ELISPOT, most of which
were directed towards Gn-derived epitopes.
With regards to the longevity of CD8 memory T cells, our
results nicely confirm a previous study by Van Epps et al. in
PUUV-convalescent patients, in which up to 100–300 SFU/10
6
PBMC of N-epitope-specific CD8 T cells were found in three
patients up to 15 years after acute infection [24,25,27]. However,
by tetramer analyses we detected still-higher frequencies with up
to 16.8% of all CD3
+CD8
+ T cells proving positive for the
single epitope Gn465–473 while displaying a late effector memory
phenotype (CD127
2CD28
2CD27
2CCR7
2). This phenotype was
in line with the cells’ ability to readily secrete granzyme B and
TNF-a without IL-2. Surprisingly, we also found that up to 5%
of tetramer
+ cells, which, again in accordance with their
CD28
+CD27
+CCR7
+CD127
+ phenotype, did not exert any
immediate effector functions, such as IFN-c secretion upon
stimulation with their cognate epitope. While these data again
show that screening by ELISPOT underestimates the real
proportion of Gn-specific T cells [35], it is also tempting to
speculate, albeit virtually impossible to prove, that patients with
either of the observed phenotypes differ at their stage of immunity
towards a possible ANDV re-challenge.
In absence of antigenic stimulation as well as of autocrine or
paracrine IL-2 and co-stimulation via CD28:B7 and CD27:CD70
interaction, late effector memory T-cells are heavily prone to
apoptosis. However, we herein were able to show in three HLA-
B*3501
+ patients that peripheral Gn465–473-specifc T cells were
maintained in the periphery for at least two years, despite a
consistent CD27
2 phenotype, thereby lacking the receptor for
crucial anti-apoptotic signals provided by CD70. While the former
perception was that senescent end-differentiated CD28
2CD27
2 T
cells were unable to divide, recent evidence suggests, that highly
differentiated granzymeB
+CD8
+ memory T cells are actually
dividing upon stimulation equally well as naı ¨ve CD8
+ T cells [54].
In man, the CD45RA
+CD28
2CD27
2CCR7
2 late effector
memory phenotype has been mainly described in patients with
latent CMV infection [37,55]. In this model repetitive or latent
antigen stimulation is supposed to drive CD8
+ memory differen-
tiation and/or the recruitment of new memory T-cells. However
human hantavirus infections are not known to cause latent or
chronic infections and we were not able to detect viral RNA in
plasma or peripheral blood cells of patients with sustained and
high T-cell responses (data not shown). Also, we failed to detect a
fingerprint of recent antigenic stimulation of tetramer-positive cells
through assessment of the expression of additional activation
markers, including CD69, CD38 and CD25. In addition,
expression of IL-7Ra (CD127) was described to be a critical
factor for long-term survival of CD8
+ memory T cells in absence
of their cognate antigen. Since CD127 is usually downregulated
upon antigen exposure and rapidly re-expressed after antigen
clearance, it is consistent that mainly virus-specific CD127
+CD8
+
memory T-cells are found in studies on Influenza-, respiratory
syncytial virus-and HBV-specificT-cells.Bycontrast, inpersistently
HIV-, CMV- or EBV-infected individuals T cells are maintained
despite their lack of CD127 expression [56,57]. Finally, KLRG1 is
mainly expressed on antigen-experienced T-cells with immediate
effector functions [55]. Thus, considering ANDV a self-limiting
transient infection in man, a CD127
+KLRG1
2 phenotype would
have been expected years after the infection. However, IFN-c
+,b u t
not IFN-c
2,G n 465–473-specific T cells expressed substantially less
CD127 than their Influenza A virus (NP418–426)-specific counter-
parts, whereas no clear pattern could be observed regarding the
KLRG1 expression. However, although no difference could be
observed between ANDV (Gn465–473)a n dI n f l u e n z a( N P 418–426)–
specific T-cells with regards to CD25, CD38 and CD69 expression,
the lack of CD127 suggests persistent antigenic stimulation in
individuals with IFN-c
+ T cells. When employing BLAST, we were
not able to identify other organisms that share the amino acid
sequence of Gn465–473, thereby making cross-reactivity an unlikely
explanation. Consistently, no further serology testing was performed
in convalescent patients.
We next hypothesized that residents of endemic areas might
have received intermittent antigen-boosters due to viral re-
exposure and therefore should show somewhat higher T-cell
responses to all viral antigens. However, we did not find significant
differences in ANDV-specific T cell numbers when comparing
patients who reside in endemic areas and those, which got during
recreation got infected in an endemic region (Fig. 7A), while
residing in non-endemic areas.
Moreover, in the majority of prospective serum samples of ten
patients from endemic regions and of seven patients from non-
endemic regions, we surprisingly found an increase in both anti-N
and NAb titers despite the fact that the second sample was taken
years after the first samples in most cases. The fact that this was
also observed in patients who never had returned to endemic
regions since their primary ANDV infection, suggests that re-
exposure to extrinsic (environmental) virus does not account for
high antibody titers and, conversely, not for high ANDV-specific
T-cell frequencies. Regarding the increase in NAb titers between
sample 1 and 2, we cannot exclude that NAb titers continued to
rise after sample 1 was drawn during or shortly after the acute
phase. Therefore, it is possible that in these patients (Fig. 7) titers of
sample 2 in fact were identical or even lower than the maximum
titer achieved during the acute phase. However, NAb titers of 13/
17 individuals were still relatively high ($1:400) at the timepoint of
sample 2, that is 1.2–11.3 years after the acute infection. This
argues for continuous antigen-exposure in both E- and R-patients,
since NAb titers, in contrast to non-neutralizing antibodies, strictly
depend on the presence of their cognate antigen. Specifically, in
absence of antigen, murine NAb titers fall below the detection
limit after 100–200 days [58]. Most importantly, however, we also
found that NAb titers increased two- to four-fold in five patients
(R1, R3, R5, E1 and E4, Fig. 7C, E) in which sample 1 was taken
months to years after the acute phase. Since not only maintenance
[58] but also kinetics of NAb titers heavily depend on the presence
of viral surface antigens [59], these results support the hypothesis
that re-exposure to viral surface (Gn/Gc) antigen is responsible for
high and rising NAb titers in both R- and E-patients. Due to the
fundamental differences between R- and E-patients in their risk for
re-exposure to extrinsic virus, this is turn suggests that intrinsic
viral antigen is responsible for the relative ‘‘immune-inflation’’ and
the terminal differentiation of Gn-specific CD8
+ T-cells. Thus, it
may be that intermittent release of low doses of viral antigen from
intrinsic virus (e.g. that never completely cleared from tissue
reservoir(s)) is sufficient to maintain and boost of NAb titers and
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sion on ANDV-specific T-cells are too short-lived (with the
exception of low CD127 expression) to be consistently different
(e.g. KLRG1) from that of Influenza A virus-specific T cells.
However, as long as viral antigen or genome cannot be detected in
convalescent patients as those described herein, the concept of
latent or persistent ANDV infection in convalescent patients
remains speculative. Future studies should therefore focus on
antigen detection in tissues (e.g. surgical or post-mortem specimen)
from solid (e.g. lung, kidney) and immuno-privileged (e.g. brain)
organs.
Our data suggest that long-lived effector memory T cells can be
maintained at high numbers in the periphery over years
independently of IL-7. Notably, our findings resemble those found
in murine Sendai and Influenza A virus infections, where epitope-
specific T-cell clonal expansions occurred in absence of antigen
throughout the CD8 memory pool [60]. As in our study, but in
contrast to models of persistent infection, clonally expanded
effector memory T-cells in these studies retained potent function-
ality despite their highly differentiated phenotype. Although we
could not formally show clonal expansion for all our patients (with
the exception of two individuals, see Fig. 8A, C) due to our non-
prospective study design, similar underlying, but yet undefined,
mechanisms may explain our findings in human ANDV infection.
The induction of a highly differentiated, resting e.g. Gn465–473–
specific, memory T-cell subset might be of major interest in the
context of vaccine development for several reasons. First, years
after infection high numbers of these CCR7
2 Gn465–473–specific
cells remain available for immuno-vigilance in the periphery.
Second, as shown, this subset possesses the ability to readily secrete
antiviral (e.g. IFN-c, TNF-a) as well as lytic (granzyme B) effector
molecules. Third, although most human studies seem to focus on
epitopes restricted to HLA-A*02 because of its wide distribution
among the Caucasian population (about 25%, [61]), it should be
noted that within the Amerindian population, the frequency of
HLA-B*35 positive individuals is about 70% higher than in
Caucasians [61]. In fact, 25% (range 22–30%) of the inhabitants in
ANDV endemic regions in Southern Chile express the HLA-B*35
and/or the HLA-A*02 allele, respectively [52]. Thus, for this
population, HLA-B*35-restricted epitopes, like Gn465–473, might
be of similar impact as HLA-A*02-restricted epitopes. However, it
first has to be established in future studies (e.g. Syrian hamster
models) whether and to which extend Gn-derived T-cell epitopes
may contribute to protective immunity. Furthermore, although
hantaviruses are not known to mutate, additional epitopes have to
be identified in future studies in order to prevent failure of a T-cell
based vaccine due to mutations within the Gn465–473 epitope.
Taken together, our results suggest that infection with ANDV
may lead to a strong highly differentiatedeffector memory response.
The findings concerning the predominant immunogenicity of
ANDV-Gn protein may have implications for the understanding
of immunity not only to ANDV, but also to other hantaviruses.
Materials and Methods
Patients, clinical classification and samples
A total of 78 patients were enrolled between 4 months and 13.2
years after hospitalization due to either mild or moderate/severe
HCPS. All patients had a previous confirmed hantavirus diagnosis
done in Chilean reference laboratories by IgG serology to SNV
and ANDV antigens by enzyme-linked immunosorbent assay
(ELISA), as previously described [62–64].
Mild HCPS was defined by the sole support of the patient by
symptomatic therapy, including respiratory support by an oxygen
mask. On the other hand, ANDV-infected patients who required
intensive care by mechanic ventilation and/or anti-shock treat-
ment with vasoactive drugs were defined as moderate/severe
HCPS.
All patients included were Chilean citizens and volunteered to
participate without receiving monetary incentive. Prior to
enrollment all patients enrolled signed informed consent, which
was previously informed by IRB committees of Clı ´nica Alemana
de Santiago, the Chilean Ministry of Health and regional IRB
committees. Before enrollment, patients were extensively informed
about the intention of the study by the local study nurse. Upon
enrollment patients did not suffer from any signs of active disease
and were only enrolled if considered healthy donors. Samples
consisted in 45 cc of peripheral venous blood, using tubes
containing Sodium Heparin (BD vacutainer). Samples were
shipped within 24 hours to our laboratory and were processed
immediately upon receipt. PBMC were isolated by Ficoll-Hypague
gradient and fresh PBMC were applied to ELISPOT assays.
PBMC, which were not used immediately were cryopreserved in
liquid nitrogen.
ELISPOT assays
96-well filterplates (Millipore) were coated with 5 mg/ml of anti-
hIFN-c (Endogen, clone M700A) or 15 mg/ml anti-granzyme B
(mabtech, clone GB10) at 4uC overnight one day prior to the
assay. For granzyme B assays, prior to coating membranes were
activated by incubation of the wells with 15 ml/well of 35%
Ethanol for 1 minute. After washing and blocking of the plate,
fresh or cryopreserved PBMC or T-cell lines were applied and
incubated for 20 hours in an incubator (Nuraire) at 37uC and
5% CO2 in the presence of 310 overlapping 15mer peptides
(Mimotopes, Australia) organized in 13 pools of 12 to 44 peptides
(final concentration 1 mg/ml, each) of continuous sequence
spanning the entire genome of the N and GPC protein of the
Chilean ANDV [30]. For mapping experiments, cells were
incubated with 10 mg/ml of each individual peptide. As negative
controls, corresponding dilutions of DMSO (Sigma) were used,
whereas a 1:100 dilution of PHA (M form, Invitrogen) was used as
positive control. After the incubation period, plates were washed
and incubated with biotinylated secondary antibodies (IFN-c:
clone M701B, granzyme B: GB11) according to the manufactur-
er’s manual. After incubation with Streptavidine-Alkaline phos-
pahtase (Vector, at 1:1000 for 2 hours), plates were incubated with
NCIP/BPT substrate (BioRad), and analyzed using the ELI.Scan
(A.EL.VIS GmbH) analyzing unit. Results were expressed as
Spot Forming Units (SFU), representing the numeric difference
between specific spots and the spots in the negative control
(DMSO).
Focus Reduction Neutralization Test (FRNT)
All FRNT studies were carried out in an approved (C20041018-
0267) biosafety level 3 laboratory. Plasma samples from the patient
were serially diluted in fourfold increments, mixed with equal
volumes of approximately 60 focus forming units (f.f.u.) of a
human Chilean virus isolate [65] before incubation on Vero E6
cells, processed and analyzed as described before [66]. The
neutralization activity of an antibody was expressed as the highest
plasma dilution capable of reducing the number of foci by at least
80%.
Intracellular cytokine staining
CryopreservedPBMCoffourdifferentpatients werechallengedin
vitro for 1.5 hours by a previously determined individual immuno-
genic peptide (10 mg/ml), the corresponding DMSO dilution or
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CD49d (clone 9F10) and anti-CD28 (clone CD28.2) (both BD
Pharmingen), respectively, and cultured for 4.5 additional hours in
the presence of GolgiStop/monensin. Finally, intracellular cytokine
staining was performed by fixation, permeabilization of cells and
subsequent staining for surface markers and intracellular IFN-c and
TNF-a according to the manufacturer’s protocol (BD, California).
Gn461–475-specific T-cell lines
2610
5 PBMC/well were stimulated with 10 mg/ml of the
Gn461–475 in the presence of 10 ng/ml IL-7 and 300 pg/ml
IL-12 (R&D systems). On day 2 after setup and every 3–4 days
10 U/ml and 150 mg/ml IL-15 were added to the culture. On day
7 and 14, T-cells were re-stimulated using irradiated (30Gy)
PBMC or irradiated autologous (100Gy) B-LCL. On day 21 T-
cells were assayed in IFN-c ELISPOT assays using truncated
peptides as indicated.
Flow cytometry, antibodies and tetramers
Was performed on a 4-colour FACSCalibur (Becton Dickinson)
or CyAn (Dako) and using either CellQuest (Becton DickinsonH)o r
Summit 4.0 (Dako) analyzing software. We used the following
antibodies (all BD Pharmingen): CD3-FITC (UCHT1), CD4-FITC
(SK3), CD45RA-FITC (HI100), CD27-FITC (M-T271), TNF-a-
FITC (Mab11), CD45RO-PE (UCHL1), CD28-PE (L293), CD8-
PercP (SK1), IFN-c-APC (B27), CD3-APC (UCHT1). FITC-,
PE- and APC- (MOPC-21) as well as PercP- (X40) conjugated
mouse IgG1k were used as isotype controls. Anti-KLRG-1-
Alexa488 was kindly provided by Prof H.P. Pircher (University of
Freiburg, Germany). Tetramer complexes were custom-synthesized
by the NIAID tetramer facility (Gaithersburg, MD) according to the
published protocol (http://research.yerkes.emory.edu/tetramer_
core/protocol.html), and Gn465–473:tetramers were either APC-
or PE-labeled. All other tetramer complexes were APC-labeled.
Table 2 shows a summary of HLA-B*3501 tetramer complexes
used in the present study.
HLA typing
The patients were genotyped for the HLA loci A, B, DRB1 and
DQB1, using the SSP PCR (Sequence Specific Primer–Polymer-
ase Chain Reaction) technique. Low and high resolution SSP kits
from Dynal (Oslo, Norway) and Invitrogen Corporation (USA)
were used.
Statistics and positivity criteria
For analysis of ELISPOT results for each patient an unpaired
Student’s t-test was applied in order to calculate significant results
as compared to the internal negative (DMSO) control. To be
evaluated as positive a sample (that is response to a individual or a
pool of up to 40 ANDV-derived 15mer peptides) had to fulfill
three criteria: (i) a significant difference (p,0.05) between sample
and negative control, (ii) specific SFU had to be superior of 50/10
6
PBMC, (iii) value had to be above a cut-off, defined as a mean +
2xSD, which was previously established in 20 healthy controls for
each peptide pool.
For differences in frequencies of tetramer cell populations an
unpaired Student’s t-test was applied. We further studied the
association of time since ANDV infection until blood sampling
with the T-cell responses against N, Gn and Gc as determined by
IFN-c ELISPOT at the time point of blood sampling. A
decreasing response with increasing time since infection corre-
sponds to a loss of T-cell memory in time and is reflected by a
negative correlation. We reject the null-hypothesis of no
association between time and the IFN-c-ELISPOT response at
the two-sided alpha level of 0.05. Due to skewness of the response
data, we log-transformed ELISPOT responses and fitted our linear
regression models on the log-transformed responses and assessed
the model assumptions by inspecting residual values against time.
Supporting Information
Figure S1 Relation between HLA-B*35 expression and ANDV-
specific T-cell responses. (A) Overall T-cell responses in HLA-
B*35-negative or (B) HLA-B*35-positive individuals according to
their clinical course of HCPS. (C) Proportion of HLA-B*35-
positive individuals with significant T-cell responses towards
Gn461–475 according to their clinical course of HCPS. Triplicates
of PBMC of each patient were challenged in a 38-hour IFN-c
ELISPOT by a total of 13 pools of overlapping peptides, spanning
the entire N- (aa 1–430), Gn- (aa 1–650) and Gc- (aa 641–1140)
protein of Chilean ANDV. Bars indicate the sum of overall
responses towards N-, Gn- and Gc-derived peptides (A, B) and
towards Gn461–475, respectively (C).
Found at: doi:10.1371/journal.ppat.1000779.s001 (0.23 MB TIF)
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